BMJ  2004;328:797 (3 April), doi:10.1136/bmj.38043.501690.7C (published 11 March 2004)

Paper

Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)

Jeffrey H Gertsch, house officer1, Buddha Basnyat, medical director2, E William Johnson, house officer3, Janet Onopa, assistant professor of medicine4, Peter S Holck, associate professor of biostatistics4, Prevention of High Altitude Illness Trial Research Group

1 Department of Internal Medicine, Maricopa Medical Center, 2601 E Roosevelt Avenue number O-D-10, Phoenix, AZ 85008, USA, 2 Himalayan Rescue Association, Kathmandu, Nepal, 3 University of Washington School of Medicine, Seattle, WA 98195-6410, USA, 4 University of Hawaii, John A Burns School of Medicine, Honolulu, Hawaii, USA

Correspondence to: J H Gertsch jeffgertsch{at}hotmail.com

Objective To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness.

Design Prospective, double blind, randomised, placebo controlled trial.

Setting Approach to Mount Everest base camp in the Nepal Himalayas at 4280 m or 4358 m and study end point at 4928 m during October and November 2002.

Participants 614 healthy western trekkers (487 completed the trial) assigned to receive ginkgo, acetazolamide, combined acetazolamide and ginkgo, or placebo, initially taking at least three or four doses before continued ascent.

Main outcome measures Incidence measured by Lake Louise acute mountain sickness score >= 3 with headache and one other symptom. Secondary outcome measures included blood oxygen content, severity of syndrome (Lake Louise scores >= 5), incidence of headache, and severity of headache.

Results Ginkgo was not significantly different from placebo for any outcome; however participants in the acetazolamide group showed significant levels of protection. The incidence of acute mountain sickness was 34% for placebo, 12% for acetazolamide (odds ratio 3.76, 95% confidence interval 1.91 to 7.39, number needed to treat 4), 35% for ginkgo (0.95, 0.56 to 1.62), and 14% for combined ginkgo and acetazolamide (3.04, 1.62 to 5.69). The proportion of patients with increased severity of acute mountain sickness was 18% for placebo, 3% for acetazoalmide (6.46, 2.15 to 19.40, number needed to treat 7), 18% for ginkgo (1, 0.52 to 1.90), and 7% for combined ginkgo and acetazolamide (2.95, 1.30 to 6.70).

Conclusions When compared with placebo, ginkgo is not effective at preventing acute mountain sickness. Acetazolamide 250 mg twice daily afforded robust protection against symptoms of acute mountain sickness.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Ginkgo biloba and acetazolamide for acute mountain sickness: Exclusion of high risk, low status groups perpetuates discrimination and inequalities
Jean Adams
BMJ 2004 329: 171. [Extract] [Full Text]

Ginkgo biloba and acetazolamide for acute mountain sickness: Bias in participants may underestimate effectiveness of agents
Heather L Elphick and David A Elphick
BMJ 2004 329: 172. [Extract] [Full Text]

Acetazolamide is better than ginkgo biloba for mountain sickness
BMJ 2004 328: 0. [Full Text]

This article has been cited by other articles:

  • Richardson, J. (2009). From the Trainer. InnovAiT 2: 414-414 [Full text]  
  • Baillie, J.K., Thompson, A.A.R., Irving, J.B., Bates, M.G.D., Sutherland, A.I., MacNee, W., Maxwell, S.R.J., Webb, D.J. (2009). Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM 102: 341-348 [Abstract] [Full text]  
  • Luks, A. M., Swenson, E. R. (2008). Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness. Chest 133: 744-755 [Abstract] [Full text]  
  • Luks, A. M., Swenson, E. R. (2007). Travel to high altitude with pre-existing lung disease. Eur Respir J 29: 770-792 [Abstract] [Full text]  
  • Spooner, L. M., Olin, J. L., Debellis, R. J. (2007). Pharmacotherapy of High-Altitude Illness. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 129-141 [Abstract]  
  • Clarke, C (2006). Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia. Postgrad. Med. J. 82: 748-753 [Abstract] [Full text]  
  • Basnyat, B. (2005). The Physiologic Basis of High-Altitude Diseases. ANN INTERN MED 142: 591-591 [Full text]  
  • West, J. B. (2005). The Physiologic Basis of High-Altitude Diseases. ANN INTERN MED 142: 592-592 [Full text]  
  • Pun, M. (2005). The Physiologic Basis of High-Altitude Diseases. ANN INTERN MED 142: 591-592 [Full text]  
  • Chow, T., Browne, V., Heileson, H. L., Wallace, D., Anholm, J., Green, S. M. (2005). Ginkgo biloba and Acetazolamide Prophylaxis for Acute Mountain Sickness: A Randomized, Placebo-Controlled Trial. Arch Intern Med 165: 296-301 [Abstract] [Full text]  
  • Elphick, H. L, Elphick, D. A (2004). Ginkgo biloba and acetazolamide for acute mountain sickness: Bias in participants may underestimate effectiveness of agents. BMJ 329: 172-172 [Full text]  
  • Adams, J. (2004). Ginkgo biloba and acetazolamide for acute mountain sickness: Exclusion of high risk, low status groups perpetuates discrimination and inequalities. BMJ 329: 171-171 [Full text]  

Rapid Responses:

Read all Rapid Responses

Number Needed to Treat
A D Martin
bmj.com, 2 Apr 2004 [Full text]
Homeopathic Coca for High Altitude Sickness
W. John Diamond
bmj.com, 2 Apr 2004 [Full text]
And those who declined to participate?
Heather L Elphick, et al.
bmj.com, 9 Apr 2004 [Full text]
Exclusion of high risk, low status groups perpetuates discrimination and inequalities
Jean Adams
bmj.com, 22 Apr 2004 [Full text]
Doc2Doc Vacancy
Access jobs at BMJ Careers
Whats new online at Student BMJ